- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03446547
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID)
November 13, 2023 updated by: Andreas Hallqvist, Vastra Gotaland Region
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC)
This is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC.
Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12 months
Study Overview
Detailed Description
This is a randomized multicentre open label phase II study of the PDL1 inhibitor Durvalumab following SBRT in patients with T1-2N0M0 NSCLC.
It will enroll 106 patients aiming at a minimum of 5 subjects per site.
The subjects will be randomized in a 1:1 fashion with performance status, gender and T-stage as stratification factors.
Patients with peripheral lung tumors will receive SBRT usually between 3 and 4 fractions.
The group randomized to immunotherapy will then receive Durvalumab, given with a fixed dose of 1500 mg i.v.
every fourth week during 12 months.
Both arms will be assessed according to the same follow-up schedule with radiology every third month.
Study Type
Interventional
Enrollment (Estimated)
106
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Andreas Hallqvist, PhD
- Phone Number: 7954 +46-31342
- Email: andreas.hallqvist@vgregion.se
Study Contact Backup
- Name: Annika Baan
- Phone Number: 0906097 +46-70
- Email: annika.baan@vgregion.se
Study Locations
-
-
-
Helsinki, Finland
- Recruiting
- Helsinki
-
Contact:
- Anu Anttonen
- Email: anu.anttonen@hus.fi
-
Tampere, Finland
- Recruiting
- Dept of Oncology
-
Contact:
- Tanja Skyttä
-
Contact:
- Email: tanja.skytta@pshp.fi
-
Turku, Finland
- Recruiting
- Turku
-
Contact:
- Maria Silvoniemi
- Email: Maria.Silvoniemi@tyks.fi
-
Vaasa, Finland
- Recruiting
- Dept of Oncology
-
Contact:
- Antti Jekunen
-
Contact:
- Email: antti.jekunen@vshp.fi
-
-
-
-
-
Oslo, Norway
- Recruiting
- Dept of Oncology
-
Contact:
- Åslaug Helland
- Email: AHH@ous-hf.no
-
Tromsø, Norway
- Recruiting
- Dept of pulmonary medicine
-
Contact:
- Nina Helbekkmo
- Email: Nina.Helbekkmo@unn.no
-
Trondheim, Norway
- Recruiting
- Dept of Oncology
-
Contact:
- Bjørn Henning Grønberg
- Email: bjorn.h.gronberg@ntnu.no
-
Ålesund, Norway
- Recruiting
- Ålesund
-
Contact:
- Øyvind Yksnøy
- Email: Oyvind.Yksnoy@helse-mr.no
-
-
-
-
-
Gävle, Sweden
- Recruiting
- Dept of pulmonary medicine
-
Contact:
- Hirsch Koyi
- Email: hirsh.koyi@regiongavleborg.se
-
Göteborg, Sweden
- Recruiting
- Dept. of Oncology
-
Contact:
- Andreas Hallqvist, PhD
- Email: andreas.hallqvist@vgregion.se
-
Linköping, Sweden
- Recruiting
- Dept of pulmonary medicine
-
Contact:
- Anders Wikström
- Email: anders.vikstrom@regionostergotland.se
-
Luleå, Sweden
- Recruiting
- Sunderbyn
-
Contact:
- Lina Lindberg
-
Contact:
-
Lund, Sweden
- Recruiting
- Dept of pulmonary medicine
-
Contact:
- Maria Planck, Ass. prof.
- Email: maria.planck@med.lu.se
-
Stockholm, Sweden
- Recruiting
- Dept of Oncology
-
Contact:
- Luigi De Petris, PhD
- Email: luigi.depetris@sll.se
-
Umeå, Sweden
- Recruiting
- Dept. of Oncology
-
Contact:
- Mikael Johansson, Ass. Prof.
- Email: mikael.b.johansson@umu.se
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Written informed consent obtained from the subject prior to performing any protocol- related procedures, including screening evaluations
- Histological or cytological diagnosis of NSCLC
- Stage I-IIA tumours ≤ 5 cm
- Peripheral tumours
- Medically inoperable patients or patients refusing surgery
- Received no prior chemotherapy or radiation therapy for NSCLC
- Age > 18 years at time of study entry, no upper age limit
- WHO performance status 0-2
- Adequate normal organ and marrow function as defined below:
- Haemoglobin ≥ 9.0 g/dL
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (> 1500 per mm3)
- Platelet count ≥ 100 x 109/L (>100,000 per mm3)
- Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
- AST/ALT ≤ 2.5 x institutional upper limit of normal
- Serum creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by chrome-EDTA or Iohexol clearance
- Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects
- Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Exclusion Criteria:
- Centrally located tumours
- No regional or distant metastases are allowed (i.e. no stage II-IV disease)
- Oxygen usage or a FEV1 < 0.7 L and CO diffusion capacity < 30%
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). Previous enrollment in the present study
- Participation in another clinical study with an investigational product during the last 4 weeks
- Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
- Second primary residual malignancy. Other malignancy diagnosed and treated > 5 years ago without relapse is allowed. (Carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin < 5 years are allowed)
- Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 28 days prior to the first dose of study drug
- Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia's Correction
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
Active or prior documented autoimmune or inflammatory disorders . The following are exceptions to this criterion:
- Subjects with vitiligo or alopecia
- Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
- Any chronic skin condition that does not require systemic therapy
- Subjects without active disease in the last 5 years may be included but only after consultation with the study physician
- Subjects with celiac disease controlled by diet alone
- History of primary immunodeficiency
- History of allogeneic organ transplant
- History of hypersensitivity to durvalumab or any excipient
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (NYHA III-IV), uncontrolled hypertension, unstable angina pectoris, interstitial lung disease, cardiac arrhythmia, active peptic ulcer disease, active bleeding diatheses
- Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
- Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
- Female subjects who are pregnant or breastfeeding or male or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.
- Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Arm A
SBRT and follow-up
|
|
Experimental: Arm B
SBRT followed by Durvalumab
|
durvalumab 1500 mg i.v.
every fourth week for 12 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TTP
Time Frame: From date of randomization until the date of first documented progression, assessed up to 60 months
|
Time to progression
|
From date of randomization until the date of first documented progression, assessed up to 60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: From date of randomization until the date of death from any cause, assessed up to 60 months
|
Overall survival
|
From date of randomization until the date of death from any cause, assessed up to 60 months
|
LC
Time Frame: Assessed at scheduled timepoints every 3-6 months through study completion (60 months)
|
Local control
|
Assessed at scheduled timepoints every 3-6 months through study completion (60 months)
|
QoL
Time Frame: Measured at baseline and at three timepoints (6, 12 and 20 months)
|
QoL by LCSS
|
Measured at baseline and at three timepoints (6, 12 and 20 months)
|
TTP by PDL1 expression
Time Frame: From date of randomization until the date of first documented progression, assessed up to 60 months
|
Time to progression related to level of PDL1expression
|
From date of randomization until the date of first documented progression, assessed up to 60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Andreas Hallqvist, PhD, Göteborg University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 4, 2017
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
February 11, 2018
First Submitted That Met QC Criteria
February 19, 2018
First Posted (Actual)
February 27, 2018
Study Record Updates
Last Update Posted (Estimated)
November 14, 2023
Last Update Submitted That Met QC Criteria
November 13, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-005225-37
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Will be available later on
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC, Stage I
-
Xiaorong DongUnknownHealthy Subjects | NSCLC Stage IV | NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage IIChina
-
The First Affiliated Hospital of Guangzhou Medical...RecruitingNSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage IIChina
-
University Hospital, EssenRecruitingNSCLC, Stage I | NSCLC Stage II | NSCLC, Stage IIIABelgium, Germany, Netherlands
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Amsterdam UMC, location VUmcUnknown
-
The Netherlands Cancer InstituteAstraZenecaUnknown
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Spanish Lung Cancer GroupCompleted
-
Niguarda HospitalUniversity of Turin, Italy; Fondazione del Piemonte per l'OncologiaCompleted
-
Shanghai Chest HospitalThe Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...RecruitingNSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIICChina
Clinical Trials on Durvalumab
-
AstraZenecaKappa SantéRecruiting
-
Yonsei UniversityRecruitingPotentially Resectable Stage II/IIIa NSCLCKorea, Republic of
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaCompletedNon-Small Cell Lung Cancer NSCLCUnited States
-
Yonsei UniversityCompleted
-
NSABP Foundation IncCompletedRectal CancerUnited States
-
Hark Kyun KimRecruiting
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
MedImmune LLCCompletedAdvanced Solid TumorsUnited States, France, Spain, Switzerland
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
AstraZenecaCompleted